$VLON News

Last published 3y ago

3y agoVLONVallon Pharmaceuticals Completes Merger with GRI Bio, Inc.GlobeNewswireCombined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T ("NKT") modulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseasesInvestment proceeds
3y agoVLONVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitGlobeNewswireVallon's board approves 1-for-30 reverse stock split Merger expected to close April 21, 2023 PHILADELPHIA, PA, April 20, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) ("Vallon" or the
3y agoVLONVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023GlobeNewswireBoard of Directors unanimously recommend Vallon stockholders to vote "FOR" all proposals outlined in the Company's definitive Proxy Statement (the "Proxy") in order to close the proposed merger with GRI Bio, Inc.
3y agoVLONVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETGlobeNewswireOver 90% of the shares voted to date have shown support "FOR" each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio PHILADELPHIA, PA, April 04, 2023
3y agoVLONVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsGlobeNewswirePHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), today reported its financial results for the fiscal year ended December 31, 2022. In
3y agoVLONVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventGlobeNewswireLive video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), and GRI Bio,
3y agoVLONVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsGlobeNewswireCombined company will operate as GRI Bio and advance innovative pipeline of Natural Killer T (NKT) regulating therapies for the treatment of inflammatory, fibrotic and autoimmune diseases GRI Bio has committed
4y agoVLONVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsGlobeNewswirePHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel
4y agoVLONVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePHILADELPHIA, PA, July 28, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoVLONVallon Pharmaceuticals Announces $3.9 Million Registered Direct OfferingGlobeNewswirePHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoVLONVallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIRGlobeNewswirePHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoVLONVallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIRGlobeNewswirePHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoVLONVallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswirePHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoCYN NILE SNAP SNDL+1Thinking about buying stock in Vallon Pharmaceuticals, Snap, Sundial Growers, Bitnile, or Cyngn?PR NewswireNEW YORK, April 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VLON, SNAP, SNDL, NILE, and CYN.
4y agoVLONVallon Pharmaceuticals Announces Review of Strategic AlternativesGlobeNewswirePhiladelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abus
4y agoVLONVallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation ForumGlobeNewswireDavid Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon"
4y agoVLONVallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHDGlobeNewswire– Study did not meet primary endpoint of significant reduction in Emax Drug Liking for ADAIR vs reference dextroamphetamine, although a trend in favor of ADAIR was observed (p=0.16) – All pharmacodynamic secondary endpoints met with st
4y agoVLONVallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of DirectorsGlobeNewswireGlobal biopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small biotech companies Philadelphia, PA, Feb. 28,
4y agoVLONVallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Associated with COVID-19GlobeNewswire- Company in ongoing discussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVID-19 PHILADELPHIA, PA, Feb. 28, 2022 (GLOBE N
4y agoVLONVallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business UpdateGlobeNewswire- Topline data for pivotal abuse study of the Company's lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with first-in-humanclinical trial expected to commence in 2022 PHILADELPH
4y agoVLONVallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks ConferenceGlobeNewswire– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company prim
4y agoVLONVallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual ConferenceGlobeNewswire- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants - Company's abuse-deterrent stimulant formulations have the potentia
4y agoAEZS AIM AREC CNSP+9JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27thACCESS Newswire- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a f
4y agoVLONVallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect ConferenceGlobeNewswirePHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse
4y agoVLONVallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIRGlobeNewswire- Topline results from pivotal SEAL study expected in Q1 2022 - If approved, ADAIR will target the growing Adderall® segment of the ~$9 billion U.S. ADHD market PHILADELPHIA, PA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceutica
4y agoALZN CTIC GRTX ONCY+1Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia TherapeuticsPR NewswirePALM BEACH, Fla., Dec. 15, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Acute Myeloid Leukemia (AML) is a type of blood cancer which usually affects white blood cells (WBCs), however, it can also start in other types of blood-forming ce
5y agoVLONVallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with selection of final formulation completed and engagem
5y agoVLONVallon Pharmaceuticals to Present at the Virtual Investor Roundtable EventGlobeNewswire- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (
5y agoVLONVallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual ConferenceGlobeNewswire- Live video webcast presentation on Monday, November 15th at 8:30 am ET PHILADELPHIA, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage biopharmaceutical company primar
5y agoAREC CNSP CRPOF CYTH+6JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18thACCESS Newswire- Access the event and schedule of presenting companies at virtualinvestorco.com -- Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 /
5y agoVLONVallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual MeetingGlobeNewswire- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medication - Company's lead investigational progr
5y agoVLONVallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate AdvancementsGlobeNewswire- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR - Company's two lead programs targeting the large
5y agoVLONVallon Pharmaceuticals Announces Formation of Scientific Advisory BoardGlobeNewswire- Inaugural appointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vall
5y agoVLONVallon Pharmaceuticals to Present at the Q3 Virtual Investor SummitGlobeNewswireLive video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage
5y agoVLONVallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the ~$9 billion US ADHD market PHILADELPHIA, PA, Aug
5y agoVLONVallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIRGlobeNewswire- Patent bolsters intellectual property protection as Company's partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON
5y agoVLONVallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswire- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs and indications PHILADELPHIA, PA, May 13
5y agoVLONVallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial OfficerGlobeNewswire- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:V
5y agoVLONVallon Pharmaceuticals to Present at the Q2 Virtual Investor SummitGlobeNewswireLive video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON), ("Vallon" or the "Company"), a clinical-stage bio
5y agoVLONVallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation ForumGlobeNewswireDavid Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:VLON), ("Vallon" or the "C
5y agoVLONVallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential ApprovalGlobeNewswire- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...
5y agoVLONVallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewswire- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...
5y agoVLONVallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswirePHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
5y agoVLONVallon Pharmaceuticals Appoints Marella Thorell to Board of DirectorsGlobeNewswire- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...
5y agoVLONVallon Pharmaceuticals Announces Closing of Initial Public OfferingGlobeNewswirePHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
5y agoVLONVallon Pharmaceuticals Announces Pricing of Initial Public OfferingGlobeNewswirePHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...